Tobias Holscher
Overview
Explore the profile of Tobias Holscher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
592
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holzschuh J, Mix M, Freitag M, Holscher T, Braune A, Kotzerke J, et al.
Radiat Oncol
. 2024 Aug;
19(1):106.
PMID: 39113123
Purpose: Convolutional Neural Networks (CNNs) have emerged as transformative tools in the field of radiation oncology, significantly advancing the precision of contouring practices. However, the adaptability of these algorithms across...
2.
Zwahlen D, Schroder C, Holer L, Bernhard J, Holscher T, Arnold W, et al.
Clin Transl Radiat Oncol
. 2024 May;
47:100786.
PMID: 38706726
Objectives: To evaluate effects of dose intensified salvage radiotherapy (sRT) on erectile function in biochemically recurrent prostate cancer (PC) after radical prostatectomy (RP). Materials And Methods: Eligible patients had evidence...
3.
Huber J, Karschuck P, Valdix J, Thomas C, Koch R, Ihrig A, et al.
BJU Int
. 2024 Mar;
134(2):239-248.
PMID: 38506410
Objective: To evaluate the nationwide online decision aid 'Entscheidungshilfe Prostatakrebs' (established in 2016, >11.000 users and 60 new users/week) for patients with non-metastatic prostate cancer (PCa), from the perspective of...
4.
Borkowetz A, Holscher T
Urologie
. 2024 Feb;
63(3):225-233.
PMID: 38388789
Background: Metastasis-directed therapy (MDT) in oligometastatic prostate cancer (omHSPC) is playing an increasingly important role in therapy with the aim of delaying disease progression, the start of systemic treatment or...
5.
Holzschuh J, Mix M, Ruf J, Holscher T, Kotzerke J, Vrachimis A, et al.
Radiother Oncol
. 2023 Jul;
188:109774.
PMID: 37394103
Purpose: With the increased use of focal radiation dose escalation for primary prostate cancer (PCa), accurate delineation of gross tumor volume (GTV) in prostate-specific membrane antigen PET (PSMA-PET) becomes crucial....
6.
Mai Y, Vogel C, Thiele J, Holscher T, Hummel T
Strahlenther Onkol
. 2023 Jun;
199(10):936-949.
PMID: 37270715
Purpose: Patients sometimes report phosphene and phantosmia during radiation therapy (RT). However, the detail features and related factors are not well understood. Our prospective study aimed to investigate the characteristics...
7.
Berthold J, Pietsch J, Piplack N, Khamfongkhruea C, Thiele J, Holscher T, et al.
Int J Radiat Oncol Biol Phys
. 2023 May;
117(3):718-729.
PMID: 37160193
Purpose: The development of online-adaptive proton therapy (PT) is essential to overcome limitations encountered by day-to-day variations of the patient's anatomy. Range verification could play an essential role in an...
8.
Klusa D, Lohaus F, Franken A, Baumbach M, Cojoc M, Dowling P, et al.
Int J Cancer
. 2023 Feb;
152(12):2639-2654.
PMID: 36733230
Ablative radiotherapy is a highly efficient treatment modality for patients with metastatic prostate cancer (PCa). However, a subset of patients does not respond. Currently, this subgroup with bad prognosis cannot...
9.
Spohn S, Draulans C, Kishan A, Spratt D, Ross A, Maurer T, et al.
Int J Radiat Oncol Biol Phys
. 2023 Jan;
116(3):503-520.
PMID: 36596346
Current risk-stratification systems for prostate cancer (PCa) do not sufficiently reflect the disease heterogeneity. Genomic classifiers (GC) enable improved risk stratification after surgery, but less data exist for patients treated...
10.
Ghadjar P, Koerber S, Holscher T, Hocht S, Wiegel T
Lancet
. 2022 Sep;
400(10356):883-884.
PMID: 36116475
No abstract available.